Portal de Periódicos da CAPES

18 F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy

2013; Society of Nuclear Medicine and Molecular Imaging; Volume: 54; Issue: 9 Linguagem: Inglês

10.2967/jnumed.112.116921

1535-5667

Edwin A. Usmanij, Lioe‐Fee de Geus‐Oei, Esther G.C. Troost, Liesbeth Peters-Bax, Erik H.F.M. van der Heijden, Johannes H.A.M. Kaanders, Wim J.G. Oyen, Olga C.J. Schuurbiers, Johan Bussink,

Lung Cancer Diagnosis and Treatment

The potential of 18 F-FDG PET changes was evaluated for prediction of response to concomitant chemoradiotherapy in patients with locally advanced non–small cell lung cancer (NSCLC). Methods: For 28 patients, 18 F-FDG PET was performed before treatment, at the end of the second week of treatment, and at 2 wk and 3 mo after the completion of treatment. Standardized uptake value (SUV), maximum SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained. Early metabolic changes were defined as fractional change (ΔTLG) when 18 F-FDG PET at the end of the second week was compared with pretreatment 18 F-FDG PET. In-treatment metabolic changes, as measured by serial 18 F-FDG PET, were correlated with standard criteria of response evaluation of solid tumors by means of CT imaging (Response Evaluation Criteria In Solid Tumors 1.1). Parameters were analyzed for stratification in progression-free survival (PFS). Results: When compared with early metabolic nonresponders, a ΔTLG decrease of 38% or more was associated with a significantly longer PFS (1-y PFS 80% vs. 36%, P = 0.02). Pretreatment TLG was found to be a prognostic factor for PFS. Conclusion: The degree of change in TLG was predictive for response to concomitant chemoradiotherapy as early as the end of the second week into treatment for patients with locally advanced NSCLC. Pretreatment TLG was prognostic for PFS.